Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial - Test2 - elhamkhani - TriplyDB

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

http://www.wikidata.org/entity/Q28300531

about

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation Postpartum misoprostol for preventing maternal mortality and morbidity Postpartum misoprostol for preventing maternal mortality and morbidity Randomisation to protect against selection bias in healthcare trials Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation Randomisation to protect against selection bias in healthcare trials A meta-analysis of the association between adherence to drug therapy and mortality Influence of physician specialty on adoption and relinquishment of calcium channel blockers and other treatments for myocardial infarction Grading quality of evidence and strength of recommendations The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute?Survival of 1476 patients initially resuscitated from out of hospital cardiac arrest Debate: Do all patients with heart failure require implantable defibrillators to prevent sudden death?Pro/con clinical debate: steroids are a key component in the treatment of SARS. Pro: Yes, steroids are a key component of the treatment regimen for SARS Methodological considerations in the design of trials for safety assessment of new drugs and chemical entities Managing atrial fibrillation in the very elderly patient: challenges and solutions Reality of evidence-based practice in palliative care Towards understanding the de-adoption of low-value clinical practices: a scoping review Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation Defective interactions of protein partner with ion channels and transporters as alternative mechanisms of membrane channelopathies Gene regulatory networks in cardiac conduction system development Challenges and opportunities in designing clinical trials for neuromyelitis optica Calmodulin-dependent protein kinase II: linking heart failure and arrhythmias Biomarkers for stroke Clinical and genetic determinants of torsade de pointes risk The perils of surrogate endpoints 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations Atrial Fibrillation: The Science behind Its Defiance When is the Best Time for the Second Antiplatelet Agent in Non-St Elevation Acute Coronary Syndrome?The current approach of atrial fibrillation management Flecainide: Current status and perspectives in arrhythmia management Perspective: a dynamics-based classification of ventricular arrhythmias 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the Ischaemic heart disease presenting as arrhythmias A monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch relief The research-treatment distinction: a problematic approach for determining which activities should have ethical oversight ST segment elevation in the right precordial leads following administration of class Ic antiarrhythmic drugs Effects of intravenous dofetilide on induction of atrioventricular re-entrant tachycardia Markov models of use-dependence and reverse use-dependence during the mouse cardiac action potential

P2860

Q24187110-B7D751EE-2468-4289-A6A2-443C1D439976 Q24197643-25C034AC-E461-4936-849A-40CD695AE277 Q24201196-873691F7-3D52-4AB0-966A-5231854C49AB Q24234524-DFA23AA4-F1C3-4A06-99E1-1B92CE51FD14 Q24235283-519C72D3-CF09-4DEE-A87F-7395A4209869 Q24243067-1CD686B8-E9F1-44C9-A7B0-AD0DCB7F4000 Q24245576-DAACD1F5-B853-414A-83CA-A0B0C2A3CCF6 Q24548922-86497565-8888-40B7-997F-B8A44B08A943 Q24550610-48528871-B3BB-41C6-A2C4-199527D40CE3 Q24562409-044F8AB2-40F5-4DC8-8FD1-C35B23DEC9CA Q24650519-B9610389-06EA-4589-89F6-DA440E980C91 Q24655344-1F82DE9A-A4C4-46CD-86D9-A1B2B2A4E043 Q24792641-A66A18B4-5A29-4F41-8421-E70832F993AB Q24805390-45E84B18-1AF4-4527-9BE2-5A53DD2C7701 Q24807158-FBCF14A0-394E-4A0A-93A0-5D70058E270D Q26775877-E70079CD-3ECB-4A0F-80A5-90F0B830F377 Q26778797-93EF412D-2B5D-469E-9650-ED6B3AFC647A Q26786656-959C10A7-7CB4-4FB3-9858-575EECB26067 Q26864767-8D8504CE-D143-4AD7-8355-7D03B60724C5 Q26866107-DA2DF958-EE01-4B69-A6A2-FBC10687AB7E Q26995702-8D37C748-38E2-416E-A427-E4F34B17BA51 Q26999708-D2CE4925-0064-4AD0-B533-11D746B89E31 Q26999872-F5B0794B-3AF7-4347-89E8-6C29907A0D6F Q27004404-D13220B7-1134-48BE-8686-088E9C297E2F Q27014821-57E4157E-1D63-4ADB-9A84-6D4231D36320 Q27025740-CCB2256B-2B1B-48F1-A4FB-9CCA65EC3B5C Q27341873-10180108-D61C-42F3-965C-3803D474DBE0 Q27860753-618665C5-97C8-430B-8A65-8640516B3DD5 Q28072139-E4BA807E-34C5-495D-89AA-F8F4898C4618 Q28072343-0AA9D54C-33E9-4143-A0F4-51B9FDB4BECB Q28076171-865216A4-9A7A-4FD6-8A2B-4016C6540A26 Q28081935-9F9480D6-BF05-407A-925B-26164CBE8952 Q28082968-A779EC79-FB82-4B32-9609-E28538D4CEBD Q28087002-A3CDD789-7690-4413-9D0B-C419A8D805A5 Q28191938-D140123C-0606-48AE-982D-A1A898A8C1A2 Q28240662-50510110-51DE-4FF1-9790-369FE679326A Q28283204-59AEB452-78D9-4064-99B6-3B6FD94AB73E Q28345168-1E66A0FB-E2F4-48C2-B1A5-4073D77855F4 Q28361787-F203A52B-6533-4E93-857B-599A0CDF69F1 Q28482100-ABBE7140-677A-4DCF-BD77-05E5D13BCFAF

P2860

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

http://www.wikidata.org/entity/Q28300531

description

1991 nî lūn-bûn

@nan

1991 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

1991 թվականի մարտին հրատարակված գիտական հոդված

@hy

1991年の論文

@ja

1991年論文

@yue

1991年論文

@zh-hant

1991年論文

@zh-hk

1991年論文

@zh-mo

1991年論文

@zh-tw

1991年论文

@wuu

name

Mortality and morbidity in pat ...... c Arrhythmia Suppression Trial

@ast

Mortality and morbidity in pat ...... c Arrhythmia Suppression Trial

@en

Mortality and morbidity in pat ...... c Arrhythmia Suppression Trial

@nl

type

label

Mortality and morbidity in pat ...... c Arrhythmia Suppression Trial

@ast

Mortality and morbidity in pat ...... c Arrhythmia Suppression Trial

@en

Mortality and morbidity in pat ...... c Arrhythmia Suppression Trial

@nl

prefLabel

Mortality and morbidity in pat ...... c Arrhythmia Suppression Trial

@ast

Mortality and morbidity in pat ...... c Arrhythmia Suppression Trial

@en

Mortality and morbidity in pat ...... c Arrhythmia Suppression Trial

@nl

P1433

Q28300531-EB5A9563-6D1D-48A3-9EC4-2F4C41741E17

P1476

Q28300531-4DF12608-2D37-4E7C-B723-5418859F533A

P2093

Q28300531-28AC6F10-130E-4F57-B1AE-31AF3072D606

Q28300531-38FA4CB9-E13F-4481-87C5-100F4868058A

Q28300531-396CD427-B1C0-46D0-93A4-BB81484E4415

Q28300531-521FEA1F-AD28-4AD2-874A-4F20334EEB4A

Q28300531-9CEB2995-C4F9-4450-B793-8A97303978F8

Q28300531-B8B29803-70FA-4C7B-9499-FF9773295ABA

Q28300531-CBEF633E-CE53-4572-A290-4F313AC36DF8

Q28300531-E44E48C3-EA7A-4836-8D10-62D9D5B75B5F

Q28300531-EEADE55E-7FA7-430C-B257-7A3D64AA51AA

Q28300531-FE90B9B6-4EE5-4DD3-B73E-A9716DD296BF

P304

Q28300531-6C8579FB-A890-4A1C-BACE-5AB58CD8530E

P31

Q28300531-C93D6965-528E-4E2C-9AD8-0C1A15BD3ABE

P3181

Q28300531-417271E4-BA1A-4962-B9A6-C0547807298A

P356

Q28300531-236D9535-7A89-4FC8-821C-60A3FA9AEF28

P407

Q28300531-AECDD5C7-FC59-4713-B534-D6DBE8920121

P433

Q28300531-19ABDEF6-ABE8-418C-A669-B3D2EE230C6A

P478

Q28300531-118F45D9-1BBC-4316-BCAB-B1CF985ED273

P577

Q28300531-B271B4ED-5B88-4215-B79E-3967595C51F3

P698

Q28300531-B8279007-92A8-40E7-AD54-15A9CCFF1DA7

P921

Q28300531-0C403740-A743-46B6-B7C3-F202425BA3D5

Q28300531-3CF24C9A-1C06-4129-96A8-8A703C44AFEC

Q28300531-D63C0AA9-A038-47E7-9D36-8E9347885BAE

P3181

P356

NEJM199103213241201

P1433

The New England Journal of Medicine

P1476

Mortality and morbidity in pat ...... c Arrhythmia Suppression Trial

@en

P2093

A Baker

http://www.w3.org/2001/XMLSchema#string

A H Barker

http://www.w3.org/2001/XMLSchema#string

D Arensberg

http://www.w3.org/2001/XMLSchema#string

D Obias-Manno

http://www.w3.org/2001/XMLSchema#string

D S Echt

http://www.w3.org/2001/XMLSchema#string

H L Greene

http://www.w3.org/2001/XMLSchema#string

L B Mitchell

http://www.w3.org/2001/XMLSchema#string

L Friedman

http://www.w3.org/2001/XMLSchema#string

P R Liebson

http://www.w3.org/2001/XMLSchema#string

R W Peters

http://www.w3.org/2001/XMLSchema#string

P304

781-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1946389

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJM199103213241201

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

324

http://www.w3.org/2001/XMLSchema#string

P577

1991-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

1900101

http://www.w3.org/2001/XMLSchema#string

P921

heart arrhythmia